UX25; D&H National Research Centers (Bird)
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Amaya, Jorge Perez
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Active, not recruiting
4
262
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Terminated
3
196
US
TC99m-tilmanocept, tilmanocept, Lymphoseek
Navidea Biopharmaceuticals
Rheumatoid Arthritis
07/24
07/24
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP
Completed
3
276
Europe, Canada, Japan, US, RoW
Depemokimab (GSK3511294), Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nasal Polyps
07/24
08/24
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT05636228: Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Completed
2
93
US, RoW
INV-102, Vehicle
Invirsa, Inc., Biomedical Advanced Research and Development Authority
Acute Infectious Keratoconjunctivitis
08/24
08/24
NCT05660265: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Recruiting
1
40
US
GSK4172239D, Placebo
GlaxoSmithKline
Hematologic Diseases, Anaemia, Sickle Cell
10/25
10/25
NCT05768113: LAEH Formulation Nasal Spray to Reduce Viral Load

Completed
N/A
30
US
Salvacion USA Inc.
Coronavirus Disease
10/21
01/22
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Terminated
N/A
715
Europe, Japan, US, RoW
THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence
Philip Morris Products S.A.
COPD, Smoking, Tobacco Use
09/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Amaya, Jorge Perez
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Active, not recruiting
4
262
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Terminated
3
196
US
TC99m-tilmanocept, tilmanocept, Lymphoseek
Navidea Biopharmaceuticals
Rheumatoid Arthritis
07/24
07/24
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP
Completed
3
276
Europe, Canada, Japan, US, RoW
Depemokimab (GSK3511294), Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nasal Polyps
07/24
08/24
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT05636228: Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Completed
2
93
US, RoW
INV-102, Vehicle
Invirsa, Inc., Biomedical Advanced Research and Development Authority
Acute Infectious Keratoconjunctivitis
08/24
08/24
NCT05660265: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Recruiting
1
40
US
GSK4172239D, Placebo
GlaxoSmithKline
Hematologic Diseases, Anaemia, Sickle Cell
10/25
10/25
NCT05768113: LAEH Formulation Nasal Spray to Reduce Viral Load

Completed
N/A
30
US
Salvacion USA Inc.
Coronavirus Disease
10/21
01/22
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Terminated
N/A
715
Europe, Japan, US, RoW
THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence
Philip Morris Products S.A.
COPD, Smoking, Tobacco Use
09/24
09/24

Download Options